

Unilife Conference Call

July 30, 2015



Cautionary Note Regarding Forward-Looking Statements

This presentation dated July 30, 2015 has been prepared by Unilife Corporation ("**Unilife or Company**") (NASDAQ: UNIS; ASX: UNIS). Statements and information in this presentation are current only as at July 30, 2015 and the information in this presentation remains subject to change without notice.

While reasonable care has been taken in relation to the preparation of this presentation, none of the Company, its subsidiaries or their respective directors, officers, employees, contractors, agents, or advisers nor any other person ("**Limited Party**") guarantees or makes any representations or warranties, express or implied, as to or takes responsibility for, the accuracy, reliability, completeness or fairness of the information, opinions, forecasts, reports, estimates and conclusions contained in this presentation. No Limited Party represents or warrants that this presentation is complete or that it contains all information about the Company that a prospective investor or purchaser may require in evaluating a possible investment in the Company or acquisition of shares in the Company. To the maximum extent permitted by law, each Limited Party expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this presentation including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom.

Certain statements in this presentation constitute forward looking statements and comments about future events, including the Company's expectations about the performance of its businesses. Such forward looking statements involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company and which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Forward looking statements are provided as a general guide only, and should not be relied on as an indication or guarantee of future performance. Given these uncertainties, recipients are cautioned to not place undue reliance on any forward looking statement. Subject to any continuing obligations under applicable law or relevant rules of the NASDAQ Stock Market or the ASX Listing Rules, the Company disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in this presentation to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based.

Agenda and Introduction

- Customer programs continue to move forward favorably
 - Manufacturing and selling products across multiple product platforms
 - From a small base, sales of prefilled syringes and wearable injectors are increasing in line with customer ramp schedules
- Well positioned for continued success through fiscal 2016 and beyond
 - Executing on current long term supply agreements
 - Building strategic relationships with new and existing customers
 - Additional capital available at Company's discretion to prudently support business growth
- Introducing an entire new category of instant patch pumps for insulin
 - Combines the therapeutic benefits of a pump with the convenience and low cost of a pen
 - Imperium: Prefilled, pre-assembled with insulin supplied ready for compact multi-day wear
 - Enables insulin providers to supply a complete insulin therapy solution directly to the patient
 - With prospective partners, Unilife can enter large, growing markets such as Type 2 diabetes that are under-served due to device complexity, reimbursement constraints and high patient costs

Unifill Shipments Increasing to Fulfill Customer Orders



- 500,000 units shipped by end of quarter
- 500,000 units expected to be shipped next quarter
- Expanding production capacity to support scheduled customer orders
- 100MM units annual capacity this year
- Continued growth over time up to 400MM units in line with multi-year ramp schedules of existing customer supply contracts



Assembly line for the Unifill Finesse™ at Unilife's facility in York, PA



One of Unilife's eleven existing clean rooms at its York, PA facility

Wearable Injectors: Shipments to Commence for Scheduled Clinical Trials

- Continuing to be selected by customers for use with their large-dose volume therapies
- Shipments for use in clinical trials scheduled to commence this quarter
 - Shipments for additional clinical trials by end of fiscal year
- Integration into high-speed drug filling and packaging lines of Cook Pharmica
 - Confirms customers can bring to market their injectable therapies with wearable injectors ready for patient self-injection
 - Pre-filled. Pre-assembled. No terminal sterilization required.
 - Video available on Unilife website



Unilife's wearable injector primary containers being filled at Cook



The qualification occurred on standard high-speed drug filling lines

Continued Investment in our Production Infrastructure in York, PA

Doubling cleanroom space and expanding building footprint to support customer scale-up needs



Installation of additional of cleanroom space in York, PA



Additional cleanrooms to support specific customer needs



Expansion of building footprint underway



Facility expansion to accommodate additional infrastructure

Financial Update

Mr. David Hastings
Chief Financial Officer



Market Segments and Product Portfolio for Injectable Drug Delivery



Prefilled Syringes with Automatic, Integrated Safety


Drug Reconstitution Delivery Systems

Auto-Injectors

Wearable Injectors

Ocular & Novel Delivery Systems

These products have not yet been reviewed by the FDA



Market Segment	CAGR	Avg. Device Unit Price*
Wearable Injectors	50-100%	\$25-\$35
Prefilled Syringes	8-14%	\$0.50-\$3
Auto Injectors	18%	Disposable \$5-\$15 Reusable up to \$500
Reconstitution Systems	9%	\$5-\$50
Ocular Delivery	23%	\$40-\$200
Novel Delivery	23%	Typically \$100+

* Roots Research. Wearable Bolus Injectors. 2014. VisionGain Medical Device Leader Series 2014-2024. Medtronic Investor Day, 2024, and Company estimates.

Market Segments and Product Portfolio for Injectable Drug Delivery



Prefilled Syringes with Automatic, Integrated Safety


Drug Reconstitution Delivery Systems

Insulin Delivery

Auto-Injectors

Wearable Injectors

Ocular & Novel Delivery Systems




Market Segment	CAGR	Avg. Device Unit Price*
Insulin Delivery Devices	5-12%	Durable: up to \$7k Patch: \$20 to \$50
Wearable Injectors	50-100%	\$25-\$35
Prefilled Syringes	8-14%	\$0.50-\$3
Auto Injectors	18%	Disposable \$5-\$15 Reusable up to \$500
Reconstitution Systems	9%	\$5-\$50
Ocular Delivery	23%	\$40-\$200
Novel Delivery	23%	Typically \$100+

* Roots Research. Wearable Bolus Injectors. 2014. VisionGain Medical Device Leader Series 2014-2024. Medtronic Investor Day, 2024, and Company estimates.

Diabetes is a Global Epidemic

“As many as one in three American adults will have diabetes in 2050 if present trends continue”

American Diabetes Association Fact Sheet, June 2014



Global Diabetes Prevalence Staggering[#]

- 1 in 11 adults (18+ years) has diabetes
- Every 7 seconds, 1 person dies from diabetes

Global and U.S. Costs of Diabetes

- 11.6% of total world healthcare expenditure is on diabetes – Totaling over \$600 Billion[#]
- Total U.S. cost up 48% in 5 years to \$322 Billion*
- Avg. burden for each American exceeds \$1,000*

Type 2 Diabetes Overwhelming Majority


- 90–95% of patients have Type 2 Diabetes
- 1 in 10 U.S. adults has Type 2 Diabetes
- Technology and innovation have traditionally focused on Type 1 Population

[#] Dall, T. Economic Burden of Elevated Blood Glucose Levels in 2012. Diabetes Care. Vol. 37. Dec 2014.

[#] IDF Diabetes Atlas. 2014


Type 2 Diabetes Population: Underserved and Ready for New Technology

20MM Insulin-Dependent Patients Worldwide Two-Thirds are in the U.S. and Europe



Improved Therapy Needed

Uncontrolled Multiple Daily Injectors (MDI) Population (U.S. & E.U.)



Better Patient Outcomes Possible But Not Achieved Through Current Therapeutic Offerings

- T2D Population Unaccepting of Traditional Pump Technology

- More than 95% of all insulin dependent T2D patients use a vial/syringe or insulin pen due to durable pump challenges:
 1. Expensive with upfront costs up to \$7,000
 2. High ongoing costs (infusion sets / other peripherals)
 3. Multiple steps to begin therapy
 4. Bulky size
 5. Complex (requires hand-held external controls and extensive training)

- Type 2 Therapy Adherence is Low


- HALF of T2D patients on insulin uncontrolled (A1C > 7%)[#]
- 72% of physicians report patients do not take insulin as prescribed, with avg. missing injections 4-6 days per month^{*}
- Injections missed due to patients:

1. Being too busy	4. Fearing pain of frequent injections
2. Traveling	5. Embarrassed to inject in public
3. Stressed by therapy	

[#] Sanofi Thematic Call on Diabetes. June 16, 2014.

^{*} Peyrot, M. Diabetes Care. Insulin adherence behaviors and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. 2023, May. 29(5)

Economic Opportunity for Primary Market Category



Primary Target Market Segment			
T2D Uncontrolled MDI			
	2020	2025	2030
Patients	4,078,000	5,235,000	6,565,000
Market Share	Potential Revenue		
5%	\$299 Million	\$383 Million	\$481 Million
10%	\$597 Million	\$766 Million	\$961 Million
15%	\$895 Million	\$1.150 Billion	\$1.442 Billion
20%	\$1.194 Billion	\$1.533 Billion	\$1.922 Billion
25%	\$1.493 Billion	\$1.916 Billion	\$2.403 Billion
30%	\$1.791 Billion	\$2.299 Billion	\$2.883 Billion
35%	\$2.090 Billion	\$2.682 Billion	\$3.364 Billion
40%	\$2.388 Billion	\$3.066 Billion	\$3.845 Billion

Economic Opportunity Growth with Other Segments

Secondary Target Market Segment			
T2D Controlled MDI			
	2020	2025	2030
Patients	3,616,000	4,642,000	5,822,000
Market Share	Potential Revenue		
5%	\$265 Million	\$340 Million	\$426 Million
10%	\$529 Million	\$680 Million	\$852 Million
15%	\$794 Million	\$1.019 Billion	\$1.279 Billion
20%	\$1.059 Billion	\$1.359 Billion	\$1.705 Billion
25%	\$1.324 Billion	\$1.699 Billion	\$2.131 Billion
30%	\$1.588 Billion	\$2.039 Billion	\$2.557 Billion
35%	\$1.853 Billion	\$2.379 Billion	\$2.983 Billion
40%	\$2.118 Billion	\$2.719 Billion	\$3.409 Billion

Tertiary Target Market Segment			
T1D Uncontrolled MDI and CSII			
	2020	2025	2030
Patients	2,274,000	2,392,000	2,516,000
Market Share	Potential Revenue		
5%	\$166 Million	\$175 Million	\$184 Million
10%	\$333 Million	\$350 Million	\$368 Million
15%	\$499 Million	\$525 Million	\$552 Million
20%	\$666 Million	\$700 Million	\$737 Million
25%	\$832 Million	\$875 Million	\$921 Million
30%	\$999 Million	\$1.050 Billion	\$1.105 Billion
35%	\$1.165 Billion	\$1.126 Billion	\$1,289 Billion
40%	\$1.331 Billion	\$1.401 Billion	\$1.473 Billion

Current Insulin Devices Fail to Meet Needs of Type 2 Patients

Multiple Daily Injections (MDI)



Syringe / Vial


Insulin Pens

Continuous Subcutaneous Insulin Infusion (CSII)



Durable Pump & Infusion Sets

Patch Pumps



A Product is Needed that Provides the Convenience, Simplicity, and Cost of an Insulin Pen with the Therapeutic Benefits of an Insulin Pump

Key Technology Drivers in Insulin Delivery Market

Reduce Complexity

- Simplify the steps to control the blood glucose level
- Lower the barriers to therapy adoption and compliance

Empower Patients


- Decrease diabetes treatment burden by improving therapy delivery and minimize patient health risk
- Prevent acute clinical events related to lack of glycemic control

Minimize Upfront and Add-On Cost

- Reduce bulk and cost of overheads (syringes, vials or extra pens)
- Remove reimbursement constraints to continuous subcutaneous insulin infusion therapy

Existing Sales and Distribution Channels

- Leverage established channels to minimize no sales, marketing, commercial development, reimbursement, and clinical support costs



**Driving market needs
for a new device
category of instant
patch pumps for insulin**

Introducing Imperium™



Delivering the therapeutic advantages of a pump,
with the simplicity and cost of a pen

Criteria for an Instant Patch Pump for Insulin

1. Prefilled and pre-assembled with standard insulin cartridge
2. Fully functional stand-alone device (no ancillary equipment)
3. No priming required by patients
4. Single push button mechanism to immediately begin therapy
5. Fully disposable
6. Low cost makes it compatible with pen reimbursement model




Imperium™ Platform – Features and Benefits for Patients



Minimal Steps to Therapy

Supplied ready for use in a fully integrated system that is prefilled with insulin. Just peel, stick and click.



Simple User Interface

A preset basal rate with on-demand bolus via a simple push of the button. No handheld controller required.



Smart-Enabled Connectivity

Wireless connectivity enables integration with smart-phone apps for patient reminders and status updates.




Convenient, Extended Wear

Highly compact in size for comfortable, discreet multi-day water-proof wear and convenient needle-free disposal


Simple Steps of Use to Begin Therapy

Peel.



Peel liner from
device

Stick.



Apply device to
body

Click.



Push button to
start basal therapy

Comparing Steps to Therapy vs. Insulin Pens and Disposable Pumps

Imperium



1

Piece of equipment

3

Steps to insulin therapy

Insulin Pens



2

Pieces of equipment

12+

Steps **per** insulin injection

Insulin Pumps*



4+

Pieces of equipment

20+

Steps to insulin therapy

* Including market-leading
insulin patch pump

Simple Steps of Use for Bolus Delivery

Press and
Hold.

Click.

Press and
Hold.



Press and hold button
to enter bolus mode



Click the button
for bolus infusion




Press and hold button
to exit bolus mode

Additional Features and Benefits for Insulin Providers



Concentrated Insulins

Prefilled, high-precision device capable of delivering highly concentrated insulins up to U-500



Standard Fill and Materials

Uses standard materials and integrates into established filling processes and equipment



Attractive for Reimbursement

Fits within therapy reimbursement model and priced significantly lower than competitive pump devices



Highly Differentiated

Visually distinctive look and feel customized to specific brand to differentiate insulin therapy from competition

Fits Seamlessly into Standard Fill Lines and Distribution Channels

Fully aligned with Unilife's B2B Model for predictable revenue and attractive operating margins



Questions

